Mirum Pharmaceuticals, Inc.

Mirum Pharmaceutical Misses on Revenue, Stock Down 2.46%

Mirum Pharmaceutical's earnings report shows a loss per share that slightly beat expectations, but the lack of revenue data and no guidance may have contributed to the stock's decline of 2.46%. Investors may be concerned about the company's future performance given the absence of revenue figures and guidance. The cautious tone from management suggests they are aware of the challenges ahead but remain focused on their long-term objectives.